Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under l-DOPA treatment

Neurotoxicity Research

Volumn 25, Issue 1, 2014, Pages 33-44

  Del Bel, Elaine ^a   Padovan Neto, Fernando Eduardo ^a   Szawka, Raphael Escorsim ^b   Da Silva, Célia Aparecida ^a   Raisman Vozari, Rita ^c,d   Anselmo Franci, Janete ^a   Romano Dutra, Angélica Caroline ^a   Guimaraes, Francisco Silveira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Dopamine replacement therapy; Dopamine turnover; l DOPA induced dyskinesia; Motor complications; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 7 NITROINDAZOLE; BENSERAZIDE; DOPAMINE; LEVODOPA; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; 7-NITROINDAZOLE; ANTIPARKINSON AGENT; ENZYME INHIBITOR; INDAZOLE DERIVATIVE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DYSKINESIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MEDIAL FOREBRAIN BUNDLE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; ROTAROD TEST; SUBSTANTIA NIGRA PARS COMPACTA; WISTAR RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; PATHOLOGY; SUBSTANTIA NIGRA; TOXICITY;

PRIMATES; RATTUS; RATTUS NORVEGICUS; RODENTIA;

ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DOPAMINE; DYSKINESIA, DRUG-INDUCED; ENZYME INHIBITORS; INDAZOLES; LEVODOPA; MALE; NITRIC OXIDE SYNTHASE; OXIDOPAMINE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

EID: 84891837456     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-013-9406-3     Document Type: Article

References (92)

1. Altar CA, Marien MR, Marshall JF (1987) Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J Neurochem 48(2):390-399 (Pubitemid 17005145)
2. Archer T, Kostrzewa RM, Beninger RJ, Palomo T (2011) Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions. Neurotox Res 19(2):211-234
3. Bergstrom BP, Garris PA (2003) Passive stabilization of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6-OHDA-lesioned rat. J Neurochem 87(5):1224-1236 (Pubitemid 37485078)
4. Bezard E, Gross CE, Brotchie JM (2003) Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26(4):215-221 (Pubitemid 36412004)
5. Bianco LE, Wiesinger J, Earley CJ, Jones BC, Beard JL (2008) Iron deficiency alters dopamine uptake and response to l-DOPA injection in Sprague-Dawley rats. J Neurochem 106(1):205-215 (Pubitemid 351840207)
6. Boireau A, Dubedat P, Bordier F, Imperato A, Moussaoui S (2000) The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology 39(6):1016-1020 (Pubitemid 30155708)
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
8. Brotchie J, Fitzer-Attas C (2009) Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 72(7 Suppl):S32-S38
9. Brun Y, Karachi C, Fernandez-Vidal S, Jodoin N, Grabli D, Bardinet E, Mallet L, Agid Y, Yelnik J, Welter ML (2012) Does unilateral basal ganglia activity functionally influence the contralateral side? What we can learn from STN stimulation in patients with Parkinson's disease. J Neurophysiol 108(6):1575
10. Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T (2003) Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 18(3):241-253 (Pubitemid 36410820)
11. Cao X, Yasuda T, Uthayathas S, Watts RL, Mouradian MM, Mochizuki H, Papa SM (2010) Striatal overexpression of DeltaFosB reproduces chronic levodopa induced involuntary movements. J Neurosci 30:7335-7343
12. Castagnoli K, Palmer S, Anderson A, Bueters T, Castagnoli N (1997) The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Chem Res Toxicol 10(4):364-368 (Pubitemid 27176296)
13. Cenci MA, Ohlin KE (2009) Rodent models of treatment-induced motor complications in Parkinson's disease. Parkinsonism Relat Disord 15(Suppl 4):S13-S17
14. Cenci MA, Tranberg A, Andersson M, Hilbertson A (1999) Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94(2):515-527 (Pubitemid 29436078)
15. Chalimoniuk M, Langfort J (2007) The effect of subchronic, intermittent l-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl cyclase expression and activity in the striatum and midbrain of normal and MPTP-treated mice. Neurochem Int 50(6):821-833 (Pubitemid 46710195)
16. Chalimoniuk M, Stepień A (2004) Influence of the therapy with pergolide mesylate plus l-DOPA and with l-DOPA alone on serum cGMP level in PD patients. Pol J Pharmacol 56(5):647-650 (Pubitemid 40123668)
17. Chalimoniuk M, Stepień A, Strosznajder JB (2004) Pergolide mesylate, a dopaminergic receptor agonist, applied with l-DOPA enhances serum antioxidant enzyme activity in Parkinson disease. Clin Neuropharmacol 27:223-229 (Pubitemid 39447219)
18. Cooper JR, Bloom FE, Roth RH (1996) The biochemical basis of neuropharmacology. Oxford University Press, New York, pp 293-351
19. de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain. 127(Pt 12):2747-2754 (Pubitemid 39627382)
20. Del-Bel EA, da Silva CA, Guimaraes FS (1998) Catalepsy induced by nitric oxide synthase inhibitors. Gen Pharmacol 30:245-248 (Pubitemid 28026728)
21. Del-Bel EA, da Silva CA, Guimaraes FS, Bermudez-Echeverry M (2004) Catalepsy induced by intra-striatal administration of nitric oxide synthase inhibitors in rats. Eur J Pharmacol 485:175-181 (Pubitemid 38134412)
22. Del-Bel EA, Guimaraes FS, Bermudez-Echeverry M, Gomes MZ, Schiaveto-de-Souza A, Padovan-Neto F, Tumas V, Barion-Cavalcanti AP, Lazzarini M, Nucci-da-Silva LP, de Paula-Souza D (2005) Role of nitric oxide on motor behavior. Cell Mol Neurobiol 25(2):371-392 (Pubitemid 40768440)
23. Del-Bel EA, Guimaraes FS, Joca SR, Echeverry MB, Ferreira FR (2010) Tolerance to the cataleptic effect that follows repeated nitric oxide synthase inhibition may be related to functional enzymatic recovery. J Psychopharmacol 24:397-405
24. Del-Bel E, Padovan-Neto FE, Raisman-Vozari R, Lazzarini M (2011) Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment. Curr Pharm Des 17(5):471-488
25. Echeverry MB, Salgado ML, Ferreira FR, da-Silva CA, Del Bel EA (2007) Intracerebroventricular administration of nitric oxide-sensitive guanylyl cyclase inhibitors induces catalepsy in mice. Psychopharmacology 194(2):271-278 (Pubitemid 47457950)
26. Finkelstein DI, Stanic D, Parish CL, Tomas D, Dickson K, Horne MK (2000) Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97(1):99-112 (Pubitemid 30195880)
27. Gomes MZ, Raisman-Vozari R, Del Bel EA (2008) A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res 1203:160-169
28. Guevara-Guzman R, Emson PC, Kendrick KM (1994) Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP. J Neurochem 62(2):807-810 (Pubitemid 24041354)
29. Handy RL, Moore PK (1997) Mechanism of the inhibition of neuronal nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole (TRIM). Life Sci 60(25):PL389-PL394
30. Hefti F, Enz A, Melamed E (1985) Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology 24(1):19-23 (Pubitemid 15162487)
31. Hornykiewicz O (1993) Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 60:140-147
32. Hornykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51(2 Suppl 2):S2-S9
33. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 65:171-222
34. Imam SZ, Islam F, Itzhak Y, Slikker W Jr, Ali SF (2000) Prevention of dopaminergic neurotoxicity by targeting nitric oxide and peroxynitrite: implications for the prevention of methamphetamine-induced neurotoxic damage. Ann N Y Acad Sci 914:157-171
35. Iravani MM, Jenner P (2011) Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm 118(12):1661-1690
36. Iravani MM, Stockwell KA, Tayarani-Binazir K, Jackson MJ, Smith LA (2008) Inhibition of neuronal nitric oxide synthase as a novel target for suppression of levoda-induced dyskinesia in primates. Neuroscience Meeting Planner Soc. Neurosc. Abstr. 139.15/M6
37. Iravani MM, McCreary AC, Jenner P (2012) Striatal plasticity in Parkinson's disease and l-DOPA induced dyskinesia. Parkinsonism Relat Disord 1:S123-S125
38. Jenner P (2008) Molecular mechanisms of l-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665-677
39. Jonkers N, Sarre S, Ebinger G, Michotte Y (2001) Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J Neural Transm 108(5):559-570 (Pubitemid 32441871)
40. Keller RW, Kuhr WG, Wightman RM, Zigmond MJ (1988) The effect of l-dopa on in vivo dopamine release from nigrostriatal bundle neurons. Brain Res 447(1):191-194
41. Lee CS, Cenci MA, Schulzer M, Björklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain. 123(Pt 7):1365-1379 (Pubitemid 30420937)
42. Lee J, Zhu WM, Stanic D, Finkelstein DI, Horne MH, Henderson J, Lawrence AJ, O'Connor L, Tomas D, Drago J, Horne MK (2008) Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinesia. Brain 131(Pt 6):1574-1587 (Pubitemid 351806467)
43. Lieu CA, Subramanian T (2012) The interhemispheric connections of the striatum: implications for Parkinson's disease and drug-induced dyskinesias. Brain Res Bull 87(1):1-9
44. Lieu CA, Deogaonkar M, Bakay RA, Subramanian T (2011) Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys. Parkinsonism Relat Disord 17(1):34-39
45. Lindgreen HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA (2010) l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112:1465-1476
46. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15(1):120-132 (Pubitemid 35478015)
47. Marin C, Rodriguez-Oroz MC, Obeso JA (2006) Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time? Exp Neurol 197:269-274 (Pubitemid 43077134)
48. Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T (2006) Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 22(3):586-598 (Pubitemid 43832130)
49. Miller DW, Abercrombie ED (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous l-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J Neurochem 72(4):1516-1522 (Pubitemid 29140823)
50. Mishra RK, Gardner EL, Katzman R, Makman MH (1974) Enhancement of dopamine-stimulated adenylate cyclase activity in rat caudate after lesions in substantia nigra: evidence for denervation supersensitivity. Proc Natl Acad Sci USA 71(10):3883-3887
51. Moore PK, Babbedge RC, Wallace P, Gaffen ZA, Hart SL (1993) 7-Nitroindazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure. Br J Pharmacol 108(2):296-297 (Pubitemid 23032528)
52. Novaretti N, Padovan-Neto FE, Tumas V, da Silva CA, Del Bel EA (2010) Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats. Braz J Med Biol Res 43(11):1047-1053
53. Obeso JA, Rodriguez-Oroz MC, Lanciego JL, Rodriguez Diaz M (2004) How does Parkinson's disease begin? The role of compensatory mechanisms. Trends Neurosci 27(3):125-127 (Pubitemid 38251511)
54. Ogawa N, Tanaka K, Asanuma M (2000) Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum. Neurochem Res 25(6):755-758 (Pubitemid 30625506)
55. Onn SP, Berger TW, Stricker EM, Zigmond MJ (1986) Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis. Brain Res 376(1):8-19 (Pubitemid 16046011)
56. Orosz D, Bennett JP (1992) Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of l-dihydroxyphenylalanine in the "hemiparkinsonian" rat. Exp Neurol 115(3):388-393
57. Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA (2009) Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neuroscience 159(3):927-935
58. Padovan-Neto FE, Echeverry MB, Chiavegatto S, Del-Bel E (2011) Nitric oxide synthase inhibitor improves de novo and long-term l-DOPA-induced dyskinesia in hemiparkinsonian rats. Front Syst Neurosci 5:40
59. Padovan-Neto FE, Ferreira NR, Tavares D, de Aguiar D, da Silva CA, Raisman-Vozari R, Del Bel E (2013) Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/delta-FosB expression. Neurosc Lett 541:126-131
60. Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, Piccini P (2006) Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 67(9):1612-1617 (Pubitemid 44747932)
61. Pavón N, Martín AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59:64-74 (Pubitemid 43005237)
62. Paxinos G, Watson W (1998) The rat brain in stereotaxic coordinates. Academic Press, San Diego
63. Pierucci M, Galati S, Valentino M, Di Matteo V, Benigno A (2011) Nitric oxide modulation of the Basal Ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. CNS Neurol Disord 10(7):777-791
64. Pifl C, Hornykiewicz O (2006) Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem Int 49(5):519-524 (Pubitemid 44189648)
65. Pritzel M, Huston JP, Sarter M (1983) Behavioral and neuronal reorganization after unilateral substantia nigra lesions: evidence for increased interhemispheric nigrostriatal projections. Neuroscience 9(4):879-888 (Pubitemid 13039170)
66. Rajput AH, Fenton ME, Di Paolo T, Sitte H, Pifl C, Hornykiewicz O (2004) Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism Relat Disord 10(4):221-226 (Pubitemid 38534615)
67. Roffler-Tarlov S, Sharman DF, Tegerdine P (1971) 3,4- Dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the mouse striatum: a reflection of intra- and extra-neuronal metabolism of dopamine? Br J Pharmacol 42(3):343-351
68. Sanchez JJ, Abreu P, Gonzalez MC (2002) Sodium nitroprusside stimulates l-DOPA release from striatal tissue through nitric oxide and cGMP. Eur J Pharmacol 438(1-2):79-83 (Pubitemid 34242922)
69. Silva MT, Rose S, Hindmarsh JG, Aislaitner G, Gorrod JW, Moore PK, Jenner P, Marsden CD (1995) Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitroindazole. Br J Pharmacol 114(2):257-258
70. Silva MT, Rose S, Hindmarsh JG, Jenner P (2003) Inhibition of neuronal nitric oxide synthase increases dopamine efflux from rat striatum. J Neural Transm 110(4):353-362 (Pubitemid 36428384)
71. Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 11(3-4):151-167
72. Soares-da-Silva P, Garrett MC (1990) A kinetic study of the rate of formation of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the brain of the rat: implications for the origin of DOPAC. Neuropharmacology 29(10):869-874 (Pubitemid 20347430)
73. Southan GJ, Szabó C (1996) Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 51(4):383-394 (Pubitemid 26071171)
74. Spadas I, Darmopil S, Vergaño-Vera E, Ortiz O, Oliva I, Vicario-Abejón C, Martín ED, Moratalla R (2012) l-DOPA-induced increase in TH-immunoreactive striatal neurons in Parkinsonian mice: insights into regulation and function. Neurobiol Dis 48(3):271-281
75. Staunton DA, Wolfe BB, Groves PM, Molinoff PB (1981) Dopamine receptor changes following destruction of the nigrostriatal pathway: lack of a relationship to rotational behavior. Brain Res 211(2):315-327 (Pubitemid 11150825)
76. Storch A, Wolz M, Beuthien-Baumann B, Löhle M, Herting B, Schwanebeck U, Oehme L, van den Hoff J, Perick M, Grählert X, Kotzerke J, Reichmann H (2013) Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Neurology 80(19):1754-1761
77. Szawka RE, Ribeiro AB, Leite CM, Helena CV, Franci CR, Anderson GM, Hoffman GE, Anselmo-Franci JA (2010) Kisspeptin regulates prolactin release through hypothalamic dopaminergic neurons. Endocrinology 151(7):3247-3257
78. Takuma K, Tanaka T, Takahashi T, Hiramatsu N, Ota Y, Ago Y, Matsuda T (2012) Neuronal nitric oxide synthase inhibition attenuates the development of l-DOPA-induced dyskinesia in hemi-Parkinsonian rats. Eur J Pharmacol 683(1-3):166-173
79. Thomas B, Saravanan KS, Mohanakumar KP (2008) In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-NI. Neurochem Int 52(6):990-1001
80. West AR, Galloway MP (1997) Endogenous nitric oxide facilitates striatal dopamine and glutamate efflux in vivo: role of ionotropic glutamate receptor-dependent mechanisms. Neuropharmacology 36(11-12):1571-1581 (Pubitemid 28085917)
81. West AR, Galloway MP, Grace AA (2002) Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse 44(4):227-245 (Pubitemid 34496647)
82. Westerink BH (1985) Sequence and significance of dopamine metabolism in the rat brain. Neurochem Int 7(2):221-227 (Pubitemid 15116200)
83. Wolf ME, Zigmond MJ, Kapatos G (1998) Tyrosine hydroxylase content of residual striatal dopamine nerve terminals following 6-hydroxydopamine administration: a flow cytometric study. J Neurochem 53(3):879-885
84. Xu ZC, Ling G, Sahr RN, Neal-Beliveau BS (2005) Asymmetrical changes of dopamine receptors in the striatum after unilateral dopamine depletion. Brain Res 1038(2):163-170 (Pubitemid 40332681)
85. Yang J, Sadler TR, Givrad TK, Maarek JM, Holschneider DP (2007) Changes in brain functional activation during resting and locomotor states after unilateral nigrostriatal damage in rats. Neuroimage 36(3):755-773 (Pubitemid 46907632)
86. Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7(4):295-309
87. Yuste JE, Bermúdez M, Bernal FR, Barcia C, Martin J, Del Bel E, Villalba EF, Herrero MT (2011) NOS inhibitors improve l-DOPA-induced dyskinesias in experimental models of Parkinsonism. Mov Disord 26(Suppl2):S257-S258
88. Zetterström T, Herrera-Marschitz M, Ungerstedt U (1986) Simultaneous measurement of dopamine release and rotational behaviour in 6-OHDA denervated rats using intracerebral dialysis. Brain Res 376(1):1-7 (Pubitemid 16046010)
89. Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM (1984) Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical Parkinsonism. Arch Neurol 41(8):856-861 (Pubitemid 14091728)
90. Zigmond MJ, Abercrombie ED, Stricker EM (1990a) Partial damage to nigrostriatal bundle: compensatory changes and the action of l-dopa. J Neural Transm 29:217-232
91. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990b) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13(7):290-296 (Pubitemid 20193461)
92. Zigmond MJ, Hastings TG, Perez RG (2002) Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat Disord 8(6):389-393 (Pubitemid 36151654)